Exendin-4 ameliorates diabetic symptoms through activation of glucokinase

Journal of Diabetes

Volumn 4, Issue 4, 2012, Pages 369-377

  Dhanesha, Nirav ^a   Joharapurkar, Amit ^a   Shah, Gaurang ^b   Dhote, Vipin ^a   Kshirsagar, Samadhan ^a   Bahekar, Rajesh ^a   Jain, Mukul ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b Institute of Pharmaceutical Education and Research   (India)

Author keywords

Diabetes; Exendin 4; Glucokinase; Liver; Pancreas

Indexed keywords

EXENDIN 4; EXENDIN 9; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOKINASE; GLUCOSE; GLYCOGEN; INSULIN; UNCLASSIFIED DRUG;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVATION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHESIS; INSULIN RELEASE; LIPID DIET; LIVER CELL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOKINASE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; PEPTIDES; VENOMS;

EID: 84870344052     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00193.x     Document Type: Article

References (41)

1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3: 153-65.
2. Drucker DJ. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003; 17: 161-71.
3. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999; 20: 876-913.
4. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117: 77-88.
5. Matschinsky FM. Banting Lecture 1995 A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes. 1996; 45: 223-41.
6. Matschinsky FM, Magnuson MA, Zelent D et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006; 55: 1-12.
7. Galan M, Vincent O, Roncero I et al. Effects of novel maturity-onset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability. Biochem J. 2006; 393: 389-96.
8. Desai UJ, Slosberg ED, Boettcher BR et al. Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. Diabetes. 2001; 50: 2287-95.
9. O'Doherty RM, Lehman DL, Seoane J, Gomez-Foix AM, Guinovart JJ, Newgard CB. Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes. J Biol Chem. 1996; 271: 20.
10. Ding SY, Nkobena A, Kraft CA, Markwardt ML, Rizzo MA. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic β-cells. J Biol Chem. 2011; 286: 768-74.
11. Lenzen S, Freytag S, Panten U. Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme. Mol Pharmacol. 1988; 34: 395-400.
12. Im Walde SS, Dohle C, Schott-Ohly P, Gleichmann H. Molecular target structures in alloxan-induced diabetes in mice. Life Sci. 2002; 71: 1681-94.
13. Zhang X, Liang W, Mao Y, Li H, Yang Y, Tan H. Hepatic glucokinase activity is the primary defect in alloxan-induced diabetes of mice. Biomed Pharmacother. 2009; 63: 180-6.
14. Murao K, Li J, Imachi H et al. Exendin-4 regulates glucokinase expression by CaMKK/CaMKIV pathway in pancreatic beta-cell line. Diabetes Obes Metab. 2009; 11: 939-46.
15. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: Duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab. 2004; 287: E75-E81.
16. Elahi D, Egan JM, Shannon RP et al.GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity. 2008; 16: 1501-9.
17. Dhanesha N, Joharapurkar A, Shah G et al. Exendin-4 reduces glycemia by increasing liver glucokinase activity: An insulin independent effect. Pharmacol Rep. 2012; 64: 140-9.
18. 2+, oxygen consumption, and insulin secretion in glucose-stimulated rat pancreatic islets. J Biol Chem. 1991; 266: 9314-19.
19. Berry MN, Friend DS. High-yield preparation of isolated rat liver parenchymal cells: A biochemical and fine structural study. J Cell Biol. 1969; 43: 506-20.
20. Davidson AL, Arion WJ. Factors underlying significant underestimations of glucokinase activity in crude liver extracts: Physiological implications of higher cellular activity. Arch Biochem Biophys. 1987; 253: 156-67.
21. Roehrig KL, Allred JB. Direct enzymatic procedure for the determination of liver glycogen. Anal Biochem. 1974; 58: 414-21.
22. Young AA, Gedulin BR, Bhavsar S et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999; 48: 1026-34.
23. Al Hasani H, Tschop MH, Cushman SW. Two birds with one stone: Novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. Mol Interv. 2003; 3: 367-70.
24. Meininger GE, Scott R, Alba M et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011; 34: 2560-6.
25. Asayama K, Nyfeler F, English D, Pilkis SJ, Burr IM. Alloxan-induced free radical production in isolated cells. Selective effect on islet cells. Diabetes. 1984; 33: 1008-11.
26. Gorus FK, Malaisse WJ, Pipeleers DG. Selective uptake of alloxan by pancreatic β-cells. Biochem J. 1982; 208: 513-15.
27. Weaver DC, McDaniel ML, Lacy PE. Alloxan uptake by isolated rat islets of Langerhans. Endocrinology. 1978; 102: 1847-55.
28. Elsner M, Tiedge M, Guldbakke B, Munday R, Lenzen S. Importance of the GLUT2 glucose transporter for pancreatic β-cell toxicity of alloxan. Diabetologia. 2002; 45: 1542-9.
29. Boquist L, Nelson L, Lorentzon R. Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro. Endocrinology. 1983; 113: 943-8.
30. Meglasson MD, Burch PT, Berner DK, Najafi H, Matschinsky FM. Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic beta-cell. Diabetes. 1986; 35: 1163-73.
31. Tiedge M, Richter T, Lenzen S. Importance of cysteine residues for the stability and catalytic activity of human pancreatic β-cell glucokinase. Arch Biochem Biophys. 2000; 375: 251-60.
32. Gunnarsson R, Hellerstrom C. Acute effects of alloxan on the metabolism and insulin secretion of the pancreatic β-cell. Horm Metab Res. 1973; 5: 404-9.
33. Hara H, Miwa I, Okuda J. Inhibition of rat liver glucokinase by alloxan and ninhydrin. Chem Pharm Bull. 1986; 34: 4731-7.
34. Iynedjian PB, Gjinovci A, Renold AE. Stimulation by insulin of glucokinase gene transcription in liver of diabetic rats. J Biol Chem. 1988; 263: 740-4.
35. Rossetti L, Lauglin MR. Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest. 1989; 84: 892-9.
36. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006; 43: 173-81.
37. Jorns A, Tiedge M, Ziv E, Shafrir E, Lenzen S. Gradual loss of pancreatic beta-cell insulin, glucokinase and GLUT2 glucose transporter immunoreactivities during the time course of nutritionally induced type-2 diabetes in Psammomys obesus (sand rat). Virchows Arch. 2002; 440: 63-9.
38. Xie W, Wang W, Su H, Xing D, Cai G, Du L. Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: Different from fibrates but similar to statins. J Pharmacol Sci. 2007; 103: 267-74.
39. Ahren B. Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. Endocrine. 1995; 3: 367-9.
40. Kim YK, Park JH, Park SH et al. Protective role of glucagon-like peptide-1 against glucosamine-induced cytotoxicity in pancreatic β-cells. Cell Physiol Biochem. 2010; 25: 211-20.
41. Balkan B, Dunning BE. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes. 1994; 43: 1173-9.